Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	23.75	33.94	46.08	74.92	10.14
Short-Term Investments	80.4	65.34	0	0	0
Cash & Cash Equivalents	104.15	99.29	46.08	74.92	10.14
Cash Growth	4.89%	115.48%	-38.50%	639.09%	-58.14%
Other Current Assets	0.68	1.54	1.84	1	-0.02
Total Current Assets	104.82	100.83	47.92	75.92	10.12
Property, Plant & Equipment	35.28	4.47	5.86	4.47	3.42
Other Long-Term Assets	2.5	4.67	1.09	0.45	1.43
Total Long-Term Assets	37.78	9.14	6.95	4.91	4.84
Total Assets	142.6	109.97	54.87	80.83	14.96
Accounts Payable	3.13	2.62	3.13	0.92	1.07
Deferred Revenue	13.79	15.35	11.72	0	0
Current Debt	5.43	1.55	1.07	0.99	0.9
Other Current Liabilities	-2.76	-5.05	2.33	2.98	3.24
Total Current Liabilities	19.6	14.47	18.25	4.88	5.21
Long-Term Debt	21.45	0.67	0.38	1.45	2.43
Other Long-Term Liabilities	12.14	14.08	1.93	0	0
Total Long-Term Liabilities	33.58	14.74	2.31	1.45	2.43
Total Liabilities	53.18	29.21	20.55	6.34	7.64
Total Debt	26.88	2.22	1.45	2.44	3.33
Debt Growth	1113.04%	52.51%	-40.43%	-26.67%	-
Retained Earnings	-311.36	-248.68	-193.4	-149.88	-127.76
Comprehensive Income	0.03	0.01	0	0	0
Shareholders' Equity	89.42	80.75	34.32	74.49	-123.34
Net Cash / Debt	77.26	97.07	44.62	72.48	6.81
Net Cash / Debt Growth	-20.40%	117.53%	-38.44%	964.20%	-71.88%
Net Cash Per Share	1.55	3.21	3.44	8.44	33.70
Working Capital	85.22	86.36	29.67	71.03	4.91
Book Value Per Share	1.79	2.67	2.64	8.67	-610.30

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).